ADORA2A and CYP24A1 demonstrated therapeutic drug synergies in advanced prostate cancer when targeted in combination with existing treatments, PARP inhibitors [96] and calcitriol [97], respectively. Here, CYP24A1 is linked to prostate carcinoma.